One-year mortality and causes of death after stereotactic radiation therapy for refractory ventricular arrhythmias: A systematic review and pooled analysis
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, systematický přehled
PubMed
38191005
DOI
10.1016/j.tcm.2023.12.008
PII: S1050-1738(23)00122-6
Knihovny.cz E-zdroje
- Klíčová slova
- Arrhythmia, Death, Heart failure, Mortality, Radiation therapy, Radioablation, Radiotherapy, Refractory, Ventricular tachycardia,
- MeSH
- časové faktory MeSH
- dospělí MeSH
- hodnocení rizik MeSH
- lidé středního věku MeSH
- lidé MeSH
- příčina smrti * MeSH
- progrese nemoci MeSH
- radiochirurgie * škodlivé účinky mortalita MeSH
- rizikové faktory MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- srdeční arytmie mortalita diagnóza patofyziologie MeSH
- srdeční selhání mortalita diagnóza patofyziologie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- systematický přehled MeSH
Patients treated with cardiac stereotactic body radiation therapy (radioablation) for refractory ventricular arrhythmias are patients with advanced structural heart disease and significant comorbidities. However, data regarding 1-year mortality after the procedure are scarce. This systematic review and pooled analysis aimed at determining 1-year mortality after cardiac radioablation for refractory ventricular arrhythmias and investigating leading causes of death in this population. MEDLINE/EMBASE databases were searched up to January 2023 for studies including patients undergoing cardiac radioablation for the treatment of refractory ventricular arrhythmias. Quality of included trials was assessed using the NIH Tool for Case Series Studies (PROSPERO CRD42022379713). A total of 1,151 references were retrieved and evaluated for relevance. Data were extracted from 16 studies, with a total of 157 patients undergoing cardiac radioablation for refractory ventricular arrhythmias. Pooled 1-year mortality was 32 % (95 %CI: 23-41), with almost half of the deaths occurring within three months after treatment. Among the 157 patients, 46 died within the year following cardiac radioablation. Worsening heart failure appeared to be the leading cause of death (52 %), although non-cardiac mortality remained substantial (41 %) in this population. Age≥70yo was associated with a significantly higher 12-month all-cause mortality (p<0.022). Neither target volume size nor radiotherapy device appeared to be associated with 1-year mortality (p = 0.465 and p = 0.199, respectively). About one-third of patients undergoing cardiac stereotactic body radiation therapy for refractory ventricular arrhythmias die within the first year after the procedure. Worsening heart failure appears to be the leading cause of death in this population.
Department of Cardiovascular Medicine Brigham and Women's Hospital Boston United States
Department of Radiation Oncology Centre Eugène Marquis Rennes France
Heart and Lung Institute Lille University Lille France
IHU LIRYC Electrophysiology and Heart Modeling Institute Bordeaux France
INSERM LTSI U1099 Rennes France
Institute for Clinical and Experimental Medicine Prague Czech Republic
Section of Cardiac Electrophysiology Dijon University Dijon France
Section of Cardiac Electrophysiology Emory University Atlanta United States
Section of Cardiac Electrophysiology Nancy University Nancy France
Section of Cardiac Electrophysiology Saint Etienne University Saint Etienne France
Citace poskytuje Crossref.org
